New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

Exercise and strength/balance training are keys to protecting against falls, but careful assessments at each clinic visit may uncover other risks to address.

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.

A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.

A panelist highlights how neffy, a needle-free, portable intranasal epinephrine device, addresses key unmet needs by reducing needle anxiety, enabling easy use by nonmedical caregivers, offering longer shelf life and temperature stability, and improving timely administration to prevent severe anaphylaxis outcomes, as demonstrated in clinical case examples.